Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 4Recruiting 3Completed 3Terminated 1Suspended 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Ovarian Neoplasms 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × fluzoparib × 1 year × Clear all
NCT05938374 2025-12-11

SPARE-03

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Completed
52 enrolled
Sarcoma

Sarcoma

NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
252 enrolled
Gynecologic

Ovarian Neoplasms

NCT04400188 2025-06-29

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Completed
25 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡